Latest News
Scholar Rock Releases SMA Community Update Letter on Apitegromab
Yesterday, Scholar Rock shared an SMA community update letter on their Biologics License Application (BLA) for apitegromab in SMA. As shared on September 23, 2025, Scholar Rock received a Complete […]
Read More ›Biogen to Initiate Phase 3 Pivotal Study Evaluating Investigational Drug Salanersen
Today, Biogen announced plans to initiate Phase 3 development to evaluate the effectiveness and safety of salanersen, an investigational drug for the treatment of spinal muscular atrophy (SMA). Phase 3 […]
Read More ›Cure SMA Updates Health Insurance Road Map to Support Patients and Families
Cure SMA has updated its Health Insurance Road Map to help patients, families, and providers navigate the complexities of health insurance. The updated resource reflects the current healthcare landscape and […]
Read More ›Cure SMA and the Luke 18:1 Foundation Launch New Fold & Go Wheelchair Grant Program
Cure SMA is excited to announce the launch of a brand-new equipment grant program, made possible through the generous support of the Luke 18:1 Foundation. This program will provide Fold […]
Read More ›Cure SMA Update on SMA Treatment Delays
Dear SMA Community, Yesterday was a disappointing and frustrating day for our community. We learned of two FDA approval delays for Scholar Rock’s apitegromab and Biogen’s high-dose nusinersen/Spinraza. While there […]
Read More ›Biogen Receives News on Supplemental New Drug Application (sNDA) for High Dose Nusinersen from the U.S. FDA
Today, Biogen announced that the U.S. Food and Drug Administration (FDA) has delayed the approval with a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) for the high-dose […]
Read More ›